CLClinicLens

Infectious Disease

Acceptability of a Dolutegravir Oral Dispersible Film in Term Neonates Born to Mothers Living With HIV. | ClinicLens

Dolutegravir (DTG) is a key antiretroviral (ARV) drug for children living with HIV, but no specific formulation is available for neonates (<28 days old). One of the DTG formulations evaluated in the PETITE-DTG trial was a novel 5 mg oral DTG dispersible film (DTG-Film). Accept

Medical Literature · Updated

← Back to articles
This standalone article is served from the ClinicLens content archive.

If the embedded page does not load in your browser, open it directly.